These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target Hayden DA; White BP; Bennett KK J Pharm Technol; 2020 Oct; 36(5):202-210. PubMed ID: 34752560 [No Abstract] [Full Text] [Related]
4. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam. Wenzler E; Scoble PJ Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557 [TBL] [Abstract][Full Text] [Related]
5. Effects of KPC Variant and Porin Genotype on the Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090 [TBL] [Abstract][Full Text] [Related]
6. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 Tiseo G; Falcone M; Leonildi A; Giordano C; Barnini S; Arcari G; Carattoli A; Menichetti F Open Forum Infect Dis; 2021 Jun; 8(6):ofab141. PubMed ID: 34189161 [TBL] [Abstract][Full Text] [Related]
7. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Tumbarello M; Raffaelli F; Cascio A; Falcone M; Signorini L; Mussini C; De Rosa FG; Losito AR; De Pascale G; Pascale R; Giacobbe DR; Oliva A; Farese A; Morelli P; Tiseo G; Meschiari M; Del Giacomo P; Montagnani F; Fabbiani M; Vargas J; Spanu T; Bassetti M; Venditti M; Viale P JAC Antimicrob Resist; 2022 Mar; 4(1):dlac022. PubMed ID: 35265842 [TBL] [Abstract][Full Text] [Related]
8. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization. Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422 [TBL] [Abstract][Full Text] [Related]
10. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Athans V; Neuner EA; Hassouna H; Richter SS; Keller G; Castanheira M; Brizendine KD; Mathers AJ Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30578403 [TBL] [Abstract][Full Text] [Related]
11. Meropenem/Vaborbactam Plus Aztreonam as a Possible Treatment Strategy for Bloodstream Infections Caused by Ceftazidime/Avibactam-Resistant Belati A; Bavaro DF; Diella L; De Gennaro N; Di Gennaro F; Saracino A Antibiotics (Basel); 2022 Mar; 11(3):. PubMed ID: 35326836 [TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755 [TBL] [Abstract][Full Text] [Related]
13. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008 [TBL] [Abstract][Full Text] [Related]
14. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam. Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562 [TBL] [Abstract][Full Text] [Related]
15. [In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates]. Hoşbul T; Aydoğan CN; Kaya S; Bedir O; Gümral R; Albay A Mikrobiyol Bul; 2022 Apr; 56(2):218-229. PubMed ID: 35477226 [TBL] [Abstract][Full Text] [Related]
16. An Update on Existing and Emerging Data for Meropenem-Vaborbactam. Shoulders BR; Casapao AM; Venugopalan V Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146 [TBL] [Abstract][Full Text] [Related]
17. Use of carbapenems in the combined treatment of emerging ceftazidime/avibactam-resistant and carbapenem-susceptible KPC-producing Klebsiella pneumoniae infections: Report of a case and review of the literature. Cano Á; Guzmán-Puche J; García-Gutiérrez M; Castón JJ; Gracia-Ahufinger I; Pérez-Nadales E; Recio M; Natera AM; Marfil-Pérez E; Martínez-Martínez L; Torre-Cisneros J J Glob Antimicrob Resist; 2020 Sep; 22():9-12. PubMed ID: 31733412 [TBL] [Abstract][Full Text] [Related]
18. Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination. Novelli A; Del Giacomo P; Rossolini GM; Tumbarello M Expert Rev Anti Infect Ther; 2020 Jul; 18(7):643-655. PubMed ID: 32297801 [TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Gaibani P; Lombardo D; Bussini L; Bovo F; Munari B; Giannella M; Bartoletti M; Viale P; Lazzarotto T; Ambretti S Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34066420 [TBL] [Abstract][Full Text] [Related]
20. Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Shields RK; Nguyen MH; Press EG; Chen L; Kreiswirth BN; Clancy CJ Open Forum Infect Dis; 2017; 4(3):ofx101. PubMed ID: 28685153 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]